Supporting patient groups and continuously improving knowledge in our therapy areas is part of our corporate responsibility.
Our ultimate goal is to discover and develop innovative therapies to improve patients' quality of life.
We specialize in the treatment of life-threatening diseases. Our patients always come first.
We offer programs for patients, families and patient organizations worldwide. They help to improve the quality of medical care.
Welcome to CSL Innovation GmbH, the Research & Development team in Marburg.
We actively promote collaborations and partnerships to bring innovation to patients.
At CSL Behring, we work every day as if someone’s life depends on it, because it does.
CSL Behring's biotherapeutics are manufactured in state-of-the-art facilities under strictly controlled conditions.
Help us deliver on our promise to save lives and protect the health of people.
We want you to feel comfortable at CSL.
Get to know us and learn more about people, projects and what happens in the world of CSL Behring.
Information for the press, such as press releases and press contact.
Popular search terms:
In healthy coagulation, the essential process stops the body from bleeding. It’s a finely tuned cascade that relies on severa…
Successful 'IBiNa on site' event in Marburg
On a campus tour, young talents from research and development gave insights into recent biomedical innovations
CSL partnered with industry and advocacy organizations in Germany to create a bold, visual demonstration of why primary immun…
HEMGENIX® for patients with severe and moderate Hemophilia B now available in Germany
Access for All: Prevention of bleeds as the global standard of care
This year’s Alpha1 Science Awards winners announced at the Annual Meeting of the German Respiratory Society
With our sustainable strategy in our Early Career Programs, we attract and develop potential future leaders for CSL Behring.
The new base fractionation in Marburg starts regular operation with a ceremonial opening.
Americas
Asia Pacific
Middle East
Europe
